Validity of different dose reduction criteria for apixaban

Nathaniel M Hawkins; Lee Er; Roopinder K Sandhu; Padma Kaul; Finlay A McAlister; Adeera Levin; Jason G Andrade

doi:10.1016/j.ahj.2021.03.004

Validity of different dose reduction criteria for apixaban

Am Heart J. 2021 Aug:238:12-15. doi: 10.1016/j.ahj.2021.03.004. Epub 2021 Mar 21.

Authors

Nathaniel M Hawkins¹, Lee Er², Roopinder K Sandhu³, Padma Kaul³, Finlay A McAlister⁴, Adeera Levin⁵, Jason G Andrade⁶

Affiliations

¹ Centre for Cardiovascular Innovation, University of British Columbia, Vancouver, British Columbia, Canada. Electronic address: nat.hawkins@ubc.ca.
² BC Renal, Vancouver, British Columbia, Canada.
³ Division of Cardiology and Mazankowski Alberta Heart Institute, University of Alberta, Edmonton, Alberta, Canada; Canadian Vigour Centre, University of Alberta, Edmonton, Alberta, Canada.
⁴ Canadian Vigour Centre, University of Alberta, Edmonton, Alberta, Canada; Division of General Internal Medicine, University of Alberta, Edmonton, Canada.
⁵ BC Renal, Vancouver, British Columbia, Canada; Division of Nephrology, Department of Medicine, University of British Columbia, Vancouver, Canada.
⁶ Centre for Cardiovascular Innovation, University of British Columbia, Vancouver, British Columbia, Canada.

PMID: 33762178
DOI: 10.1016/j.ahj.2021.03.004

Abstract

Reduced-dose apixaban is recommended in patients fulfilling 2 of 3 criteria: age ≥80 years, body weight ≤60 kg, and serum creatinine ≥1.5 mg/dL. However, patient weight is often not available in electronic health data. We examined the validity of alternative definitions based on age and renal function alone using an observational dataset of patients with atrial fibrillation and chronic kidney disease which included weight measurements.

Publication types

Letter
Observational Study

MeSH terms

Age Factors*
Aged, 80 and over
Atrial Fibrillation / complications*
Body Weight*
British Columbia
Creatinine / blood*
Drug Tapering
Factor Xa Inhibitors / administration & dosage*
Female
Glomerular Filtration Rate
Humans
Male
Pyrazoles / administration & dosage*
Pyridones / administration & dosage*
Renal Insufficiency, Chronic / blood
Renal Insufficiency, Chronic / complications*
Sex Factors
Thromboembolism / etiology
Thromboembolism / prevention & control

Substances

Factor Xa Inhibitors
Pyrazoles
Pyridones
apixaban
Creatinine